LATHAM&WATKINS LLP

April 27, 2011

VIA EDGAR CORRESPONDENCE

Ms. Sasha S. Parikh Staff Accountant Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549

Re: Amgen Inc.

Form 10-K for the Year Ended December 31, 2010

Definitive Proxy filed April 7, 2011

File No. 0-12477

Dear Ms. Parikh:

If you have any questions or comments with regard to this response or other matters, please call the undersigned at (714) 755-8245.

Very truly yours,

/s/ Charles K. Ruck

Charles K. Ruck

of LATHAM & WATKINS LLP

650 Town Center Drive, 20th Floor Costa Mesa, California 92626-1925 Tel: +1.714.540.1235 Fax: +1.714.755.8290

FIRM / AFFILIATE OFFICES

Munich New Jersey

New York

Riyadh Rome San Diego

Orange County Paris

San Francisco Shanghai Silicon Valley

Washington, D.C.

Singapore

Tokyo

www.lw.com

Abu Dhabi

Barcelona Beijing

Brussels

Chicago

Doha

Dubai

Frankfurt Hamburg

Hong Kong

Los Angeles

Houston London

Madrid

Milan

On behalf of Amgen Inc. (the "Company"), we are responding to your letter dated April 15, 2011 regarding the review of the above-referenced filings. Pursuant to our exchange of voicemails today, the Company hereby confirms that it will provide the Staff of the Division of Corporate Finance with the Company's response to the Staff's comments on or before May 13, 2011.

David J. Scott, Esq., Amgen Inc.